Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors - Related Studies

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

This study has been completed.

Study NCT00033241. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Pancreatic Cancer

2	Additional conditions recognized in this trial
		Pancreatic Neoplasms

3	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Neoplasms
		Neoplasms by Site
		Pancreatic Diseases

4	Interventions listed in this trial
		erlotinib hydrochloride
		gemcitabine hydrochloride

5	Additional drug interventions recognized in this trial
		Erlotinib
		Gemcitabine

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protein Kinase Inhibitors
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		OSI Pharmaceuticals